NCT05655949 is a Phase 2 clinical trial of Gemcitabine in Bile Duct Cancer, sponsored by Beth Israel Deaconess Medical Center.

Who is sponsoring NCT05655949?

NCT05655949 is sponsored by Beth Israel Deaconess Medical Center.

What drugs are being tested in NCT05655949?

Interventions in NCT05655949: Gemcitabine, Cisplatin, Durvalumab, Yttrium-90.

What condition does NCT05655949 study?

NCT05655949 studies Bile Duct Cancer, Cholangiocarcinoma, Cholangiocarcinoma Non-resectable, Cholangiocarcinoma Metastatic, Metastatic Intrahepatic Cholangiocarcinoma.

Is NCT05655949 still recruiting?

NCT05655949 is currently recruiting now. Last updated 10 March 2025.

Last reviewed 2025-03-10 · How we verify

NCT05655949

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio

Recruiting now Phase 2 Last updated 10 March 2025

What this trial tests

Phase 2 trial testing Gemcitabine in Bile Duct Cancer in 30 participants. Currently enrolling.

Timeline

13 February 2024

Primary endpoint
1 December 2026

1 December 2027

Quick facts

Lead sponsor	Beth Israel Deaconess Medical Center
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	30
Start date	13 February 2024
Primary completion	1 December 2026
Estimated completion	1 December 2027
Sites	1 location across United States

Drugs / interventions tested

Gemcitabine (gemcitabine) — full drug profile →
Cisplatin (cisplatin) — full drug profile →
Durvalumab — full drug profile →
Yttrium-90

Conditions studied

Bile Duct Cancer — all drugs for Bile Duct Cancer →
Cholangiocarcinoma — all drugs for Cholangiocarcinoma →
Cholangiocarcinoma Non-resectable — all drugs for Cholangiocarcinoma Non-resectable →
Cholangiocarcinoma Metastatic — all drugs for Cholangiocarcinoma Metastatic →

Sponsor

Beth Israel Deaconess Medical Center

Who can join

18 and older, any sex, with Bile Duct Cancer or Cholangiocarcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This trial is designed to study a combination of interventions (chemotherapy, immunotherapy, and radiation) as a potential new treatment for bile duct cancer that cannot be removed with surgery. The specific names of the interventions that will be used are: * Y-90 (a type of radiation microsphere bead) * Durvalumab (a type of immunotherapy) * Gemcitabine (a type of chemotherapy) * Cisplatin (a type of chemotherapy)

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Current and Emerging Therapeutic Targets for the Treatment of Cholangiocarcinoma: An Updated Review.
Hadfield MJ, DeCarli K, Bash K, Sun G, et al · · 2023 · cited 12× · PMID 38203714 · DOI 10.3390/ijms25010543
Update on Locoregional Therapies for Cholangiocellular Carcinoma.
Morawitz J, Bruckmann NM, Jannusch K, Kirchner J, et al · · 2023 · cited 5× · PMID 37190295 · DOI 10.3390/cancers15082368
Conversion treatment for advanced intrahepatic cholangiocarcinoma: Opportunities and challenges.
Liu JJ, Zhou M, Yuan T, Huang ZY, et al · · 2025 · cited 3× · PMID 40309227 · DOI 10.3748/wjg.v31.i15.104901
Research hotspots and trends in immunotherapy for cholangiocarcinoma: a bibliometric analysis (2014-2023).
Qu X, Wang Q, Zhu F, Liang H, et al · · 2024 · cited 2× · PMID 39660136 · DOI 10.3389/fimmu.2024.1436315

Verify or expand the search:

Other trials of Gemcitabine

Trials testing the same drug.

NCT07365306 — Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant · Phase 2 · not yet recruiting
NCT07504588 — Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and · Phase 2 · not yet recruiting
NCT07492680 — A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic S · Phase 2 · not yet recruiting
NCT07275216 — Pembrolizumab in Combination With Chemotherapy for the Treatment of Frail Hodgkin Lymphoma Patients Ineligible for Stand · Phase 2 · not yet recruiting
NCT07286266 — A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Platinum-resistant Ovarian Cancer (BEH · Phase 3 · not yet recruiting

Other recruiting trials for Bile Duct Cancer

Currently open trials in the same condition.

NCT07155525 — Tissue Adhesive Glue Modified Cyanoacrylate (Glubran® 2) in Soft Pancreas · Phase 3 · recruiting
NCT05849480 — A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects W · Phase 1, PHASE2 · recruiting
NCT06277531 — Evaluation of diagnostiC Capacity of eccDNAs as Biomarkers in Indetermined biLiary Stricture(ECCBILE) · recruiting
NCT06043466 — A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors · Phase 1 · recruiting
NCT05858736 — Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors · Phase 1 · active not recruiting

Other Beth Israel Deaconess Medical Center trials

Trials by the same sponsor.

NCT07352657 — Remote Alert Pathway To Optimize CaRe of Cardiac Implantable Electrical Devices: The RAPTOR-CIED Study (Main Phase) · NA · not yet recruiting
NCT07531602 — Effect of PEEP on Cardiac Function · NA · not yet recruiting
NCT07534683 — Primed to Thrive: Investigating the Combined Impact of Mindfulness Education and Meditation Practice on Psychological an · NA · not yet recruiting
NCT07277244 — Low-Intensity Mechanical Ventilation in the Operating Room: a Pilot Study · NA · enrolling by invitation
NCT06896474 — SDM POSSIBLE: A Breast Cancer Treatment Decision Aid for Women 70+ With Low-Risk Stage I Breast Cancers · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05655949 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Beth Israel Deaconess Medical Center
Last refreshed: 10 March 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05655949.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing